Bolt Biotherapeutics, Inc. BOLT

First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 resultsCash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027 REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second

VANCOUVER, BC / ACCESS Newswire / June 12, 2026 /Bolt Metals Corp. ("Bolt" or the "Company") (CSE:BOLT)(OTCQB:PCRCF)(FSE:A3D8AK), is pleased to announce that, further to its press releases dated May 13, 2026, the letter of intent dated October 23, ...

The metastatic HER2-positive breast cancer market outlook continues to be promising, supported by ongoing innovation, expanding therapeutic indications, lifecycle management initiatives, and increasing demand for more effective and patient-friendly HER2-targeted treatments, including SYD985 (trastuzumab duocarmazine) (Byondis), Giredestrant (Roche), ARX788 (Ambrx), IBRANCE (palbociclib) (Pfizer), BDC-1001 ± pertuzumab (Bolt Biotherapeutics), BI-1607 + Trastuzumab (BioInvent International AB), an

First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into 2027, including completion of the dose escalation portion of the ongoing BDC-4182 Phase 1/2 study REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment

VANCOUVER, BC / ACCESS Newswire / April 9, 2026 /Bolt Metals Corp. ("Bolt" or the "Company") (TSXV:BOLT)(OTCQB:PCRCF)(FSE:A3D8AK), a North American mineral acquisition and exploration company, is pleased to announce the appointment of Mr. Rick Mah ...

First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash balance of $31.8 million as of December 31, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full